Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: NAI operates in two primary segments: private label contract manufacturing (providing manufacturing services for nutritional supplements) and branded products (marketing and distributing its own brands, including the "Dr. Cherry Pathway to Healing" line and the "As We Change" catalog). The company is headquartered in San Marcos, California, with significant operations in Europe (NAIE).
Key Financial Metrics
| Metric | Q1 FY2008 (Ended Sep 30, 2007) | Q1 FY2007 (Ended Sep 30, 2006) |
|---|---|---|
| Net Sales | $25,521,000 | $25,161,000 |
| Gross Profit | $5,295,000 | $5,515,000 |
| Gross Margin | 20.7% | 21.9% |
| Operating Income | $670,000 | $832,000 |
| Net Income | $423,000 | $387,000 |
| Diluted EPS | $0.06 | $0.05 |
| Cash and Equivalents | $3,240,000 | $2,000,000 (End of period) |
| Total Debt | $4,148,000 | $4,585,000 (End of prior period) |
| Operating Cash Flow | ($578,000) Used | $7,661,000 Provided |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total net sales increased 1% year-over-year. Private label contract manufacturing sales grew 4% (driven by higher volumes from Mannatech and Arbonne), while branded products sales declined 12% (primarily due to the cessation of Dr. Cherry's television program in April 2007).
- Margin Compression: Gross profit margin decreased 1.2 percentage points to 20.7%. This was driven by a shift in sales mix toward lower-margin private label products and increased indirect labor costs for management strengthening in operations and quality control.
- Cash Flow Volatility: Operating cash flow swung from a positive $7.7 million in the prior year to a negative $0.6 million. The primary driver was a $1.5 million increase in accounts receivable (cash used) compared to $6.4 million in collections (cash provided) in the prior year.
- Interest Expense Reduction: Net other expense decreased significantly ($201,000) due to lower interest expense from reduced line of credit utilization and a $94,000 increase in foreign exchange gains.
Guidance, Outlook, and Risks
- Revenue Outlook: Management expects a reduction in net sales of approximately $3 million to $5 million in the second quarter of fiscal 2008 compared to the same period in fiscal 2007. This decline is attributed to a single contract manufacturing customer.
- Strategic Focus: The company plans to leverage its certified facilities to attract new private label customers, implement initiatives to sustain the "Pathway to Healing" product line, and evaluate acquisition opportunities.
- Customer Concentration Risk: The company faces significant dependency on a few customers. Three customers accounted for 81% of total net sales in the quarter (Customer 1: 36%, Customer 2: 34%, Customer 3: 11%).
- Internal Control Weakness: Management concluded that disclosure controls and procedures were not effective as of September 30, 2007. A material weakness was identified regarding the annual goodwill impairment analysis process, which delayed the filing of the 2007 Annual Report.
- Market Risks: The company is exposed to foreign currency fluctuations (Swiss Franc and Euro) and interest rate changes on variable-rate debt.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the top two customers (representing 70% of sales) and the impact of the anticipated $3M-$5M revenue drop in Q2.
- Dr. Cherry Product Line: Assess the effectiveness of new marketing strategies to replace the lost television program revenue for the "Pathway to Healing" line.
- Internal Controls: Monitor the remediation plan for the material weakness in goodwill impairment analysis and the timeline for regaining effective disclosure controls.
- Liquidity Position: Review the trend in accounts receivable days sales outstanding (43 days vs. 72 days prior year) to ensure cash flow conversion improves despite the current operating cash outflow.
- Debt Covenants: Confirm compliance with the 1.25/1.0 total liabilities to tangible net worth covenant and the fixed charge coverage ratio.